ß-d-N4-hydroxycytidine (NHC), the parent nucleoside of molnupiravir, a COVID-19 antiviral, was quantified at SARS-CoV-2 transmission sites in 12 patients enrolled in AGILE Candidate-Specific Trial-2. Saliva, nasal, and tear NHC concentrations were 3%, 21%, and 22% that of plasma. Saliva and nasal NHC were significantly correlated with plasma (P < .0001). Clinical Trials Registration. NCT04746183.
Keywords: COVID-19; SARS-CoV-2; molnupiravir; nonplasma; pharmacokinetics.
© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America.